Biography:Edgar G. Engleman
Edgar G. Engleman (born 1945) is an American pathologist and physician-scientist who researches cancer immunology. He is a professor of pathology and of medicine (immunology and rheumatology) at Stanford University School of Medicine.[1] He is also a co-founder of Vivo Capital, a Healthcare Investment firm.[2]
Life
Engleman earned a B.A., magna cum laude, from Harvard College in 1967.[3] He completed a M.D. from the Columbia University College of Physicians & Surgeons in 1971.[3] He was an intern in medicine at Moffitt Hospital, University of California, San Francisco from 1971 to 1972.[3] This was followed by a residency at the University of California Hospital in San Francisco from 1972 to 1973.[3] Engleman was a research associate in the laboratory of biochemistry under Earl Reece Stadtman at the National Heart, Lung, and Blood Institute from 1973 to 1976.[3] He was a postdoctoral fellow in immunogenetics and rheumatology under Hugh McDevitt at the Stanford University School of Medicine from 1976 to 1978.[3]
After studying immunology as a post-doctoral fellow, in 1978, Engleman became a faculty member in the department of pathology.[4][3] He was an assistant professor of pathology and medicine.[3] He was promoted to professor with tenure in 1990. The same year, he won an NIH MERIT award.[3]
At Stanford University, Engleman has been researching the immune system and its role in diseases for forty years.[4] Since 1980 he has been the founding director of the Stanford Blood Center,[1] which allowed him to access immune cells (or white blood cells) for his immunological research.[4] He moved into the field of cancer biology.[4] He directs the Engleman Lab, focusing on studying the cellular immunology of cancer.[5] His research was the basis for the first active immunotherapeutic strategy for cancer to be approved by the FDA in 2010.[6]
Selected works
- Engleman, Edgar G., ed (1980) (in en). Genetic Control of the Human Immune Response: Proceedings a Conference Sponsored by the Kroc Foundation, Santa Ynes Valley, California 28 Jan-1 Feb 1980. 152. Rockefeller University Press.
- Engleman, Edgar G., ed (1985) (in en). Human Hybridomas and Monoclonal Antibodies. Boston, MA: Springer US. doi:10.1007/978-1-4684-4949-5. ISBN 978-1-4684-4951-8.
References
- ↑ 1.0 1.1 "Edgar Engleman". https://med.stanford.edu/profiles/edgar-engleman.
- ↑ "Fireside Chat：Entrepreneuership". November 19, 2022. https://tibia.org.tw/wp-content/uploads/2022/10/TiBIA-Fireside-Chat%E8%AD%B0%E7%A8%8B-1.pdf.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Engleman, Edgar G.. "Curriculum Vitae". https://cap.stanford.edu/profiles/viewCV?facultyId=4490&name=Edgar_Engleman.
- ↑ 4.0 4.1 4.2 4.3 "Dr. Edgar Engleman: Advancing the Field of Cancer Immunology - NCI" (in en). 2022-11-21. https://www.cancer.gov/about-nci/organization/dcb/research-programs/csbc/ed-engleman.
This article incorporates text from this source, which is in the public domain.
- ↑ "Engleman Lab". https://med.stanford.edu/englemanlab.html.
- ↑ "Dr. Edgar Engleman" (in en-US). https://stanfordbloodcenter.org/leadership/dr-edgar-engleman/.
This article incorporates public domain material from websites or documents of the National Institutes of Health.
 |  |
